نتائج البحث 311-320 من 16819 لعملية البحث عن immunothérapie
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients ... Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a phase II multi ...
Cohort A: Colorectal cancer (CRC);; Cohort B: Gastric and gastroesophageal junction (GEJ) cancer;; Cohort C: Triple-negative breast cancer (TNBC);; Cohort D: ...
Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...
Levels of bladder cancer-derived extracellular vesicles become undetectable after radical cystectomy in patients with localized bladder cancer. This study hopes ...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come ...
The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill ...
The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall ...
Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.